Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

MIV in polymer-free DES (drug-eluting stent) trial:

This article was originally published in Clinica

Executive Summary

As part of its bid to bring to market technology that it claims could lead to improved drug-eluting stents (DESs), MIV Therapeutics has performed the first-in-man implant of its polymer-free DES. The MIVT Pilot Trial, which is being conducted in Brazil, will evaluate the safety and efficacy of the device in patients with single de novo lesions in their native coronary arteries. The product combines the company's GenX coronary stent with one of its hydroxyapatite polymer-free drug-eluting systems that is 700 nanometers thin. The Atlanta, Georgia firm believes its new class of polymer-free DESs could provide patients with superior outcomes.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT048508

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel